BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23568456)

  • 21. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
    Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
    Chiappella A; Dodero A; Evangelista A; Re A; Orsucci L; Usai SV; Castellino C; Stefoni V; Pinto A; Zanni M; Ciancia R; Ghiggi C; Rossi FG; Arcari A; Ilariucci F; Zilioli VR; Flenghi L; Celli M; Volpetti S; Benedetti F; Ballerini F; Musuraca G; Bruna R; Patti C; Leonardi F; Arcaini L; Magagnoli M; Cavallo F; Bermema A; Tucci A; Boccomini C; Ciccone G; Carniti C; Pileri SA; Corradini P
    Leukemia; 2023 Feb; 37(2):433-440. PubMed ID: 36653509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
    Beaven AW; Diehl LF
    Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
    Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
    Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Treatment of Peripheral T-cell Lymphoma.
    Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
    Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
    Hapgood G; Latimer M; Lee ST; Kuss B; Lade S; Tobin JWD; Purtill D; Campbell BA; Prince HM; Hawkes EA; Shortt J; Radeski D
    Intern Med J; 2022 Oct; 52(10):1806-1817. PubMed ID: 34668281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
    Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
    Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
    Sharma M; Pro B
    Curr Treat Options Oncol; 2015 Jul; 16(7):34. PubMed ID: 26076798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T-cell lymphoma--not otherwise specified.
    Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
    Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
    Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
    Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
    Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
    Yam C; Landsburg DJ; Nead KT; Lin X; Mato AR; Svoboda J; Loren AW; Frey NV; Stadtmauer EA; Porter DL; Schuster SJ; Nasta SD
    Am J Hematol; 2016 Jul; 91(7):672-6. PubMed ID: 27012928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stem cell transplantation for peripheral T-cell lymphomas.
    Jantunen E; D'Amore F
    Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of high-dose therapy in peripheral T-cell lymphomas.
    Reimer P; Rüdiger T; Wilhelm M
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
    Franco CM; Popplewell LL; Horwitz SM
    Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.